Rituximab — Drug Intelligence | 188 EU Trials

Filter these 188 trials by condition, phase, country and more.

Open in Search →

188 Registered trials

85 Recruiting

84 Completed trials

105 Sponsors

25 Countries

Phase III

Phase II

Phase III: 80 Phase II/III: 11 Phase II: 62 Phase I/II: 10 Phase III/IV: 4 Phase IV: 15 Phase I (FiH): 6

Oversight events:

6 serious breaches 26 temporary halts 5 urgent safety measures 15 unexpected events 6 corrective measures across 23 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 21 Mantle cell lymphoma 7 Follicular lymphoma 6 Diffuse large B-cell lymphoma refractory 4 Marginal zone lymphoma 4 Systemic lupus erythematosus 3 High-grade B-cell lymphoma 3 B-cell lymphoma refractory 3 Nephrotic syndrome 3 Rheumatoid arthritis 3 Follicle centre lymphoma follicular grade I II III 3 Relapsing-remitting multiple sclerosis 3

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 8 F. Hoffmann-La Roche AG 7 Fondazione Italiana Linfomi Ets 6 LYSARC 6 AbbVie Deutschland GmbH & Co. KG 5 BeOne Medicines AG 5 Novartis Pharma AG 5 Celgene Corp. 4 Centre Hospitalier Universitaire De Nantes 4 Kite Pharma Inc. 4 Merck Sharp & Dohme LLC 4 Regeneron Pharmaceuticals Inc. 4

All trials

188 total

The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nep… Not authorised

2024-511214-20-00 Phase II 1 country Ospedale Pediatrico Bambino Gesu'
A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending

2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending

2024-513445-37-00 Phase III 4 countries University Of Cologne
ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending

2024-513824-41-00 Phase IV 4 countries Semmelweis University
Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending

2024-516052-17-01 Phase II/III 1 country Hospital Foch
Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study Pending

2024-516335-27-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending

2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous syst… Pending

2024-519046-79-00 Phase II 1 country Oulu University Hospital
HiHat trial Pending

2024-519700-28-01 Phase II 1 country Region Uppsala
A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de no… Pending

2025-520641-69-00 Phase II 3 countries Medizinische Universitaet Innsbruck
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Phase II/III 1 country Assistance Publique Hopitaux De Paris
The REFINE study Pending

2025-522133-66-00 Phase III 1 country Karolinska University Hospital
A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending

2025-522595-87-00 Phase I (FiH) 2 countries Daiichi Sankyo Inc.
Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending

2025-523389-26-00 Phase III 8 countries Deciphera Pharmaceuticals Inc.
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept Pending

2025-523465-21-00 Phase III 1 country Region Stockholm – SLSO
A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment … Pending

2025-523892-50-00 Phase III 1 country Region Stockholm – SLSO
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Phase III 2 countries Innocare Pharma Inc.
A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Phase III 2 countries Dizal (Jiangsu) Pharmaceutical Co. Ltd.
A randomized controlled phase II, double blinded trial to investigate pulmonary function after treatment with rituximab compared to placebo … Recruiting

2024-517667-23-00 Phase II 4 countries Oslo University Hospital HF
A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting

2025-520461-41-00 Phase II 8 countries Artiva Biotherapeutics Inc.
Clinical trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms o… Recruiting

2024-511983-97-00 Phase II 2 countries Fundacion Geltamo
A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting

2024-514084-26-00 Phase III 3 countries Ascentage Pharma Group Inc.
Rituximab and obinutuzumab in SLE Recruiting

2024-518965-85-00 Phase IV 1 country Amsterdam UMC Stichting

Showing 1–24 of 188 trials

← All drugs A–Z